DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Sponsor: Primus Pharmaceuticals
Terminated
Not able to recruit patients with the current enrollment criteria.
Other terminated trials from Primus Pharmaceuticals
Other Plaque Psoriasis trials with similar outcome
Listed as NCT02527421, this PHASE3 trial focuses on Plaque Psoriasis and remains terminated or withdrawn. Sponsored by Primus Pharmaceuticals, it has been updated 12 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE3
-
Nov 2021 — Apr 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Nov 2021 [monthly]
Terminated PHASE3
▶ Show 7 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Apr 2020 — Oct 2020 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2018 — Apr 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Primus Pharmaceuticals
- Prosoft Clinical
For direct contact, visit the study record on ClinicalTrials.gov .